NYSE$MDT
Medtronic PLC · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Medtronic's Q1 2023 financial results were reported, with revenue exceeding guidance despite supply chain challenges. Notable strength was seen in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe.
Medtronic's Q1 2023 revenue reached $7.371 billion, a decrease of 8% as reported and 4% organically. GAAP diluted EPS increased by 25% to $0.70, while non-GAAP diluted EPS decreased by 17% to $1.13. The company reiterated its FY23 revenue and EPS guidance.
- GAAP diluted EPS of $0.70 increased 25%; non-GAAP diluted EPS of $1.13 decreased 17%, in-line with expectations
- Revenue of $7.4 billion decreased 8% as reported and 4% organic, ahead of expectations
- Company reiterates FY23 revenue and EPS guidance
- Supply chain is improving and confident in ability to accelerate growth.
Headline financials
Revenue & EPS history
Medtronic · Revenue · Quarterly
$7.37B
Revenue by segment
Medtronic · $7.37B total across 9 segments · Q1 2023
- Cardiac Rhythm & Heart Failure$1.39B-6.1%18.9%
- Surgical & Endoscopy$1.34B-13.9%18.2%
- Cranial & Spinal Technologies$1.04B-7.1%14.2%
- Structural Heart & Aortic$741M-5.8%10.1%
- Specialty Therapies$667M+4.1%9.0%
- Other$664M-13.5%9.0%
- Coronary & Peripheral Vascular$579M-6.6%7.9%
- Diabetes$541M-5.4%7.3%
- Neuromodulation$405M-8.0%5.5%
Forward guidance
Medtronic reiterated its revenue growth and EPS guidance ranges for fiscal year 2023. The company continues to expect organic revenue growth in the range of 4% to 5%.
Tailwinds
- Company continues to expect organic revenue growth in its fiscal year 2023 in the range of 4% to 5%.
- Expect organic revenue growth to improve each quarter
- Second half of the fiscal year much stronger than the first
- Focused on identifying ways to offset their impact to our financials
- Optimistic about our future, as we create markets and realize new opportunities.
Headwinds
- Fiscal year 2023 revenue growth would be negatively affected by approximately $1.4 billion to $1.5 billion versus the previously stated $1.0 to $1.1 billion impact from foreign currency exchange rates.
- Company continues to expect fiscal year 2023 diluted non-GAAP EPS in the range of $5.53 to $5.65, including an estimated 17 to 22 cent negative impact from foreign currency.
- Markets are facing macroeconomic challenges
- Impact to certain procedure volumes
- Macroeconomic impacts of inflation and foreign currency translation
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-0.2%
Avg return
Earnings day
-0.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
57%
37 / 65 earnings
Positive
+6.2%
Q1 2019
Best reaction
-7.3%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -2.8% | -2.6% | -12.7% | |
| Q2 2026 | +3.9% | +5.1% | +2.3% | |
| Q1 2026 | -3.1% | -0.1% | +3.0% | |
| Q4 2025 | -2.2% | -6.6% | -0.0% | |
| Q3 2025 | -7.3% | -3.1% | -1.7% | |
| Q2 2025 | -4.0% | -1.6% | -8.7% | |
| Q1 2025 | +3.2% | +4.2% | +5.5% | |
| Q4 2024 | -4.0% | -4.4% | -4.8% | |
| Q3 2024 | +1.8% | +1.5% | -1.2% | |
| Q2 2024 | +4.3% | +5.1% | +9.0% | |
| Q1 2024 | +2.5% | +0.7% | -1.4% | |
| Q4 2023 | -6.9% | -5.7% | -0.0% | |
| Q3 2023 | +0.4% | -1.5% | -8.5% | |
| Q2 2023 | -4.0% | -3.9% | -6.3% | |
| Q1 2023 | -4.1% | -3.9% | -10.2% | |
| Q4 2022 | -6.1% | -5.1% | -14.5% | |
| Q3 2022 | +2.4% | +5.2% | +5.7% | |
| Q2 2022 | -2.1% | -5.0% | -12.0% | |
| Q1 2022 | +4.7% | +4.1% | +1.7% | |
| Q4 2021 | +0.3% | -0.8% | +2.8% | |
| Q3 2021 | +2.6% | +1.1% | +0.7% | |
| Q2 2021 | +2.1% | +3.3% | +2.8% | |
| Q1 2021 | +3.9% | +7.7% | +1.1% | |
| Q4 2020 | -3.4% | -0.9% | -4.3% | |
| Q3 2020 | -3.0% | -3.5% | -32.5% | |
| Q2 2020 | +0.5% | -0.4% | +2.0% | |
| Q1 2020 | +3.5% | +1.8% | +6.6% | |
| Q4 2019 | +4.8% | +2.9% | +12.0% | |
| Q3 2019 | +0.6% | +1.6% | -0.2% | |
| Q2 2019 | +2.9% | +1.8% | -0.5% | |
| Q1 2019 | +6.2% | +6.1% | +8.3% | |
| Q4 2018 | +1.2% | +0.2% | +1.8% | |
| Q3 2018 | -3.1% | -3.5% | -6.2% | |
| Q2 2018 | +4.4% | +5.5% | +3.3% | |
| Q1 2018 | -4.5% | -5.3% | -4.8% | |
| Q4 2017 | +0.5% | +0.2% | +5.3% | |
| Q3 2017 | +0.9% | +2.7% | +2.5% | |
| Q2 2017 | -6.0% | -6.3% | -11.0% | |
| Q1 2017 | -0.1% | +0.2% | +1.2% | |
| Q4 2016 | -1.4% | +1.5% | +6.2% | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -3.6% | — | — | |
| Q4 2015 | +0.2% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | +3.7% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.2% | — | — | |
| Q2 2014 | -2.4% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +3.3% | — | — | |
| Q3 2013 | -5.0% | — | — | |
| Q2 2013 | +1.6% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +2.0% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | -3.2% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -0.2% | — | — | |
| Q1 2010 | +1.5% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro